Related references
Note: Only part of the references are listed.Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer
Troels K. Bergmann et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy
Kyu-pyo Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
Anne-Joy M. de Graan et al.
CLINICAL CANCER RESEARCH (2012)
Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics
Martin N. Fransson et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
The European Medicines Agency Review of Cabazitaxel (Jevtana®) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean et al.
ONCOLOGIST (2012)
The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients
Sin-Chi Chew et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
Martin N. Fransson et al.
DRUG METABOLISM AND DISPOSITION (2011)
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
T. K. Bergmann et al.
PHARMACOGENOMICS JOURNAL (2011)
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
S. Leskelae et al.
PHARMACOGENOMICS JOURNAL (2011)
ABC transporter gene expression in benign and malignant ovarian tissue
Veronika Auner et al.
GYNECOLOGIC ONCOLOGY (2010)
Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel
Robert A. B. van Waterschoot et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
H. Chang et al.
ANNALS OF ONCOLOGY (2009)
Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
Henrik Green et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2009)
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms
Shih-Meng Tsai et al.
CLINICA CHIMICA ACTA (2009)
Pharmacogenetic Pathway Analysis of Docetaxel Elimination
S. D. Baker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study
Hee Seung Kim et al.
GYNECOLOGIC ONCOLOGY (2009)
Taxane pathway
Connie Oshiro et al.
PHARMACOGENETICS AND GENOMICS (2009)
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel
Tristan M. Sissung et al.
CLINICAL CANCER RESEARCH (2008)
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
Tristan M. Sissung et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood—brain barrier
Dirk M. Hermann
Therapeutic Advances in Neurological Disorders (2008)
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
Sharon Marsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
S. Marsh et al.
PHARMACOGENOMICS JOURNAL (2007)
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers
Mari Jiko et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
Lionel D. Lewis et al.
CLINICAL CANCER RESEARCH (2007)
Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay
Hotcherl Jeong et al.
PLOS GENETICS (2007)
Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics
N. F. Smith et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
In-vitro transport characteristics discriminate wild-type ABCB1 (MRD1) from ALA893SER and ALA893THR polymorphisms
Melanie Schaefer et al.
PHARMACOGENETICS AND GENOMICS (2006)
A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant HEK cells
Matthew H. Crouthamel et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Tristan M. Sissung et al.
EUROPEAN JOURNAL OF CANCER (2006)
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics
Jurjen S. Lagas et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel
Tessa M. Bosch et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacokinetics and toxicity of docetaxel:: Role of CYP3A, MDR1, and GST polymorphisms
A Tran et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species
H Tabata
CURRENT DRUG TARGETS (2006)
Peripheral neuropathy induced by microtubule-stabilizing agents
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression
PF Song et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
A Henningsson et al.
CLINICAL CANCER RESEARCH (2005)
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
NF Smith et al.
CANCER BIOLOGY & THERAPY (2005)
Preclinical pharmacology of the taxanes: Implications of the differences
J Gligorov et al.
ONCOLOGIST (2004)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
MF Fromm
ADVANCED DRUG DELIVERY REVIEWS (2002)
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies
BC Goh et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays
GE Sandusky et al.
HISTOPATHOLOGY (2002)
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system
C Kimchi-Sarfaty et al.
MOLECULAR PHARMACOLOGY (2002)
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933
L van Zuylen et al.
EUROPEAN JOURNAL OF CANCER (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Enterohepatic circulation - Physiological, pharmacokinetic and clinical implications
MS Roberts et al.
CLINICAL PHARMACOKINETICS (2002)
The human ATP-binding cassette (ABC) transporter superfamily
M Dean et al.
GENOME RESEARCH (2001)
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
G Somlo et al.
BRITISH JOURNAL OF CANCER (2001)
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers
T Abe et al.
GASTROENTEROLOGY (2001)
Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide
J König et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
